Jesus Berdeja, MD
Findings presented during the 2017 ASH Annual Meeting generated excitement in the field, says Jesus Berdeja, MD. Some of the most impactful data presented included the ALCYONE study and the dose-escalation study of the BCMA-directed CAR T-cell therapy bb2121.
during the 2018 State of the Science Summit™ on Hematologic Malignancies, Berdeja, director of Multiple Myeloma Research at Sarah Cannon Research Institute, reflected on these pivotal studies in multiple myeloma and discussed potential advancements in the upcoming year.
OncLive: Can you share your insight on some of the recent advances in myeloma?
The 2017 ASH Annual Meeting was very good for myeloma—we had a lot of exciting things happen. [Some] were simple things that may make a big splash in the treatment of myeloma in the field of supportive care. One of the things that we struggle with in myeloma are infections. There were 2 studies presented [at the meeting]; the first was with antibiotics in the first 3 months from diagnosis, which significantly decreased morbidity and mortality in myeloma. A simple intervention like an antibiotic can make a significant difference. The other study looked at the influenza vaccination in patients with myeloma. It looks like if you give the high-dose vaccination and a booster 30 days later, you get a significantly greater amount of protection than with just 1 dose. Again, this is another simple intervention that can make a big difference in our patients.
... to read the full story